poisar

Stocks · News reference

Niki BioSolutions’ DiamiR Biosciences Agrees To Provide Progressive Medical Research With Apolipoprotein E Genotyping Services In Support Of Ongoing Clinical And Translational Research Programs

Benzinga Newsdesk

Partnership Expands Access to Clinically Critical Genetic Testing in Support of Leading Research ProgramsNEW HAVEN, CT and PRINCETON, NJ, July 23, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc., a clinical-stage life

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NIKI
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — Niki BioSolutions, Inc. (NIKI)

    Filed: 2026-09-04 AccNo: 0001213900-26-097705 Size: 473 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

    NIKI